Success Factors for Technology Transfer Start-Up Companies
14 September 2023 | 10am
With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry,improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel will foster conversation about best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.
Panelists:
- Abe Bassan, MS, Vice President, Samsara BioCapital
- Peter M. Pellerito, Senior Policy Advisor, Federal/State Economic Development & Technology Transfer Lead, BIO
- Gayatri Varma, PhD, Executive Director, Head of Transactions, Oncology Business Development & Licensing, AstraZeneca
- James Zanewicz, Chief Business Officer, Tulane University School of Medicine
Speakers Include:
- Srini Akkaraju, MD, PhD, Founder and Managing Partner, Samsara BioCapital
- Peter Pellerito, Senior Policy Adviser Federal/State Economic Development & Technology Transfer Lead, Biotechnology Innovation Organization (BIO)
- Gayatri Varma, PhD, Executive Director, Head of Transactions, Oncology Business Development & Licensing, AstraZeneca
- James Zanewicz, Chief Business Officer, Tulane University School of Medicine; Co-Chair of BIO’s Technology Transfer Committee
The panel will cover the following topics and take audience questions:
- Best practices for start-ups pursuing translational research to raise capital and find development guidance
- New BIO survey data on the bottlenecks hindering progress for tech transfer start-ups seeking industry partners
- Advice for connecting with venture investors interested in start-ups based on academia-sourced IP